D

Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192

Watchlist Manager
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Watchlist
Price: 45.1 CNY -3.34% Market Closed
Market Cap: 18.7B CNY
Have any thoughts about
Dizal Jiangsu Pharmaceutical Co Ltd?
Write Note

Dizal Jiangsu Pharmaceutical Co Ltd
Other Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Dizal Jiangsu Pharmaceutical Co Ltd
Other Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Receivables CAGR 3Y CAGR 5Y CAGR 10Y
D
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Other Receivables
ÂĄ37.5m
CAGR 3-Years
297%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Other Receivables
ÂĄ685.6m
CAGR 3-Years
55%
CAGR 5-Years
50%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Other Receivables
ÂĄ92.2m
CAGR 3-Years
36%
CAGR 5-Years
33%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Other Receivables
ÂĄ185.2m
CAGR 3-Years
-12%
CAGR 5-Years
-9%
CAGR 10-Years
21%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Other Receivables
ÂĄ8m
CAGR 3-Years
-17%
CAGR 5-Years
-34%
CAGR 10-Years
-23%
Imeik Technology Development Co Ltd
SZSE:300896
Other Receivables
ÂĄ24.8m
CAGR 3-Years
17%
CAGR 5-Years
39%
CAGR 10-Years
N/A
No Stocks Found

Dizal Jiangsu Pharmaceutical Co Ltd
Glance View

Market Cap
18.4B CNY
Industry
Biotechnology

Dizal (Jiangsu) Pharmaceutical Co., Ltd. engages in the discovery, development, and commercialization of innovative medicines. The company is headquartered in Shanghai, Shanghai and currently employs 328 full-time employees. The company went IPO on 2021-12-10. The firm focuses on diseases such as malignant tumors and immune diseases. The main candidate innovative drugs in the Company's research and development (R&D) pipeline are DZD4205, DZD9008, DZD1516, DZD2269, DZD8586, DZD0095. The firm is still in the R&D stage.

Intrinsic Value
30.31 CNY
Overvaluation 33%
Intrinsic Value
Price
D

See Also

What is Dizal Jiangsu Pharmaceutical Co Ltd's Other Receivables?
Other Receivables
37.5m CNY

Based on the financial report for Dec 31, 2023, Dizal Jiangsu Pharmaceutical Co Ltd's Other Receivables amounts to 37.5m CNY.

What is Dizal Jiangsu Pharmaceutical Co Ltd's Other Receivables growth rate?
Other Receivables CAGR 3Y
297%

The average annual Other Receivables growth rates for Dizal Jiangsu Pharmaceutical Co Ltd have been 297% over the past three years .

Back to Top